Zusammenfassung
Ein 35-jähriger Mann bemerkt vier Wochen vor der Erstvorstellung eine Sehverschlechterung des linken Auges. 14 Tage später verschlechtert sich auch das Sehen des rechten Auges. Allgemein sei er gesund. Bis vor Kurzem habe er relativ viel Rum und Wodka konsumiert, bis vor Kurzem ca. vier Schachteln Zigaretten pro Tag konsumiert. Ein Bruder sei an LHON erkrankt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Amore G, Romagnoli M, Carbonelli M, et al. Therapeutic options in hereditary optic neuropathieserapeutic options in hereditary optic neuropathies. Drugs. 2021;81:57–86.
Biousse V, Newman NJ, Yu-Wai-Man P, et al. Long-term follow-up after unilateral intravitreal gene therapy for leber hereditary optic neuropathy: the RESTORE study. J Neuroophthalmol. 2021;41(3):309–15.
Carelli V, Carbonelli M, de Coo IF, et al. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. J Neuroophthalmol. 2017;37:371–81.
Catarino CB, von Livonius B, Priglinger C, et al. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol. 2020;40:558–65.
Gerber S, Ding MG, Gérard X, et al. Compound heterozygosity for severe and hypomorphic NDUFS2 mutations cause non-syndromic LHON-like optic neuropathy. J Med Genet. 2017;54:346–56.
Newman NJ, Yu-Wai-Man P, Carelli V, et al. Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021a;128:649–60.
Newman NJ, Yu-Wai-Man P, Carelli V, et al. Intravitreal gene therapy vs. natural history in patients with leber hereditary optic. Neuropathy carrying the m.11778G>A ND4 mutation: systematic review and indirect comparison. Front Neurol. 2021b;12:662838.
Oliveira C. Toxic-metabolic and hereditary optic neuropathies. Continuum (Minneap Minn). 2019a;25:1265–88.
Oliveira C. Toxic-metabolic and hereditary optic neuropathies. Continuum (Minneap Minn). 2019b;5:1265–88.
Pallotta MT, Tascini G, Crispoldi R, et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med. 2019;23(17):238.
Rigoli L, Bramanti P, Di Bella C, et al. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83:921–9.
Romagnoli M, La Morgia C, Carbonelli M, et al. Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy. Ann Clin Transl Neurol. 2020;7:590–4.
Sarzi E, Seveno M, Piro-Mégy C, et al. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model. Sci Rep. 2018;8:2468.
Tonagel F, Wilhelm H, Richter P, Kelbsch C. Leber’s hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation. Graefes Arch Clin Exp Ophthalmol. 2021;259:1009–13.
Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771–86.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Steffen, H., Rüther, K. (2023). Genetisch-bedingte Optikusatrophien. In: Steffen, H., Kelbsch, C., Tonagel, F., Job, O. (eds) Neuroophthalmologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-64261-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-64261-0_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-64260-3
Online ISBN: 978-3-662-64261-0
eBook Packages: Medicine (German Language)